Soiken Holdings Inc. Logo

Soiken Holdings Inc.

Commercializes medical research via biomarker tech, clinical services, and products.

2385 | T

Overview

Corporate Details

ISIN(s):
JP3431850001
LEI:
Country:
Japan
Address:
豊中市新千里東町一丁目4番2号

Description

Soiken Holdings Inc. is a holding company focused on commercializing outcomes from medical science research. The group's core competency lies in the development and application of biomarker technology and related bioassay systems. Through its subsidiaries, the company provides a range of services, including clinical evaluation and testing for pharmaceutical and food manufacturers, and support for clinical research. In addition to its service-based operations, Soiken Holdings develops and markets its own evidence-based products. These include functional dietary supplements, high-functionality cosmetics, and functional materials for various applications. The company is also engaged in advanced research and development in areas such as gene therapy and novel pharmaceutical compounds.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-09-29 02:18
内部統制報告書-第27期(令和2年7月1日-令和3年6月30日)
Japanese 22.7 KB
2021-09-29 02:18
確認書
Japanese 8.2 KB
2021-09-29 02:17
有価証券報告書-第27期(令和2年7月1日-令和3年6月30日)
Japanese 871.5 KB
2021-05-13 03:24
四半期報告書-第27期第3四半期(令和3年1月1日-令和3年3月31日)
Japanese 152.8 KB
2021-02-12 01:36
四半期報告書-第27期第2四半期(令和2年10月1日-令和2年12月31日)
Japanese 183.8 KB
2020-11-13 01:52
四半期報告書-第27期第1四半期(令和2年7月1日-令和2年9月30日)
Japanese 146.6 KB
2020-09-28 02:44
確認書
Japanese 8.1 KB
2020-09-28 02:40
有価証券報告書-第26期(令和1年7月1日-令和2年6月30日)
Japanese 858.5 KB
2020-09-28 02:40
内部統制報告書-第26期(令和1年7月1日-令和2年6月30日)
Japanese 22.7 KB
2020-05-14 04:04
四半期報告書-第26期第3四半期(令和2年1月1日-令和2年3月31日)
Japanese 146.8 KB
2020-02-13 01:43
四半期報告書-第26期第2四半期(令和1年10月1日-令和1年12月31日)
Japanese 174.2 KB
2019-11-13 06:01
四半期報告書-第26期第1四半期(2019/07/01-2019/09/30)
Japanese 140.7 KB
2019-09-27 02:48
有価証券報告書-第25期(平成30年7月1日-令和1年6月30日)
Japanese 840.4 KB
2019-05-14 03:21
四半期報告書-第25期第3四半期(2019/01/01-2019/03/31)
Japanese 150.6 KB
2019-02-13 05:18
四半期報告書-第25期第2四半期(2018/10/01-2018/12/31)
Japanese 180.4 KB

Automate Your Workflow. Get a real-time feed of all Soiken Holdings Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Soiken Holdings Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Soiken Holdings Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.